chloroquine has been researched along with Lupus Nephritis in 6 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
Lupus Nephritis: Glomerulonephritis associated with autoimmune disease SYSTEMIC LUPUS ERYTHEMATOSUS. Lupus nephritis is histologically classified into 6 classes: class I - normal glomeruli, class II - pure mesangial alterations, class III - focal segmental glomerulonephritis, class IV - diffuse glomerulonephritis, class V - diffuse membranous glomerulonephritis, and class VI - advanced sclerosing glomerulonephritis (The World Health Organization classification 1982).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Chloroquine has been reported to protect against renal damage in lupus nephritis (LN); however, its detailed mechanism in glomerular inflammation remains unclear." | 7.85 | Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis. ( Hayakari, R; Imaizumi, T; Kawaguchi, S; Matsumiya, T; Tanaka, H; Tsuruga, K; Watanabe, S; Yoshida, H, 2017) |
| "Although anti-malarial agents, chloroquine (CQ) and hydroxychloroquine (HCQ) are currently used for the treatment of systemic lupus erythematosus, their efficacy for lupus nephritis (LN) remains unclear." | 4.02 | Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokines via Toll-like receptor 3 signaling in human glomerular endothelial cells. ( Aizawa, T; Imaizumi, T; Kawaguchi, S; Matsumiya, T; Sato, R; Seya, K; Tanaka, H; Tsugawa, K; Watanabe, S, 2021) |
| "Chloroquine has been reported to protect against renal damage in lupus nephritis (LN); however, its detailed mechanism in glomerular inflammation remains unclear." | 3.85 | Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis. ( Hayakari, R; Imaizumi, T; Kawaguchi, S; Matsumiya, T; Tanaka, H; Tsuruga, K; Watanabe, S; Yoshida, H, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sato, R | 1 |
| Imaizumi, T | 2 |
| Aizawa, T | 1 |
| Watanabe, S | 2 |
| Tsugawa, K | 1 |
| Kawaguchi, S | 2 |
| Seya, K | 1 |
| Matsumiya, T | 2 |
| Tanaka, H | 2 |
| Hayakari, R | 1 |
| Yoshida, H | 1 |
| Tsuruga, K | 1 |
| Madhok, R | 1 |
| Wu, O | 1 |
| Tang, C | 1 |
| Godfrey, T | 1 |
| Stawell, R | 1 |
| Nikpour, M | 1 |
| Sisó, A | 1 |
| Ramos-Casals, M | 1 |
| Bové, A | 1 |
| Brito-Zerón, P | 1 |
| Soria, N | 1 |
| Muñoz, S | 1 |
| Testi, A | 1 |
| Plaza, J | 1 |
| Sentís, J | 1 |
| Coca, A | 1 |
| Köstler, E | 1 |
| Heinicke, HJ | 1 |
| Schneider, F | 1 |
| Riedel, H | 1 |
| Hensel, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "A Clinical Evaluation of the Safety and Efficacy of Randomized Placebo Versus the 8-aminoquinoline Tafenoquine for Early Symptom Resolution in Patients With Mild to Moderate COVID 19 Disease and Low Risk of Disease Progression (the ACLR8-LR Study)"[NCT05947812] | Phase 2 | 148 participants (Anticipated) | Interventional | 2023-08-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for chloroquine and Lupus Nephritis
| Article | Year |
|---|---|
Systemic lupus erythematosus.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Chloroquine; Humans; Hydroxychloro | 2009 |
Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.
Topics: Antimalarials; Carbohydrate Metabolism; Cardiovascular Diseases; Chloroquine; Clinical Trials as Top | 2012 |
4 other studies available for chloroquine and Lupus Nephritis
| Article | Year |
|---|---|
Inhibitory effect of anti-malarial agents on the expression of proinflammatory chemokines via Toll-like receptor 3 signaling in human glomerular endothelial cells.
Topics: Antimalarials; Cell Line; Cells, Cultured; Chemokine CCL5; Chemokines; Chloroquine; Endothelial Cell | 2021 |
Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis.
Topics: Antirheumatic Agents; Cells, Cultured; Chloroquine; Humans; Interferon-beta; Lupus Nephritis; Mesang | 2017 |
Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
Topics: Adolescent; Adult; Aged; Antimalarials; Biopsy; Child; Chloroquine; Disease Progression; Female; Fol | 2008 |
[Porphyria cutanea tarda and lupus erythematosus].
Topics: Adult; Biopsy; Chloroquine; Cyclophosphamide; Humans; Kidney; Liver; Liver Function Tests; Lupus Ery | 1989 |